52 completed, 18 active not recruiting, 10 terminated, 8 recruiting. 44 Phase 2, 26 Phase 1, 15 Not applicable, 8 Phase 3, 2 Early Phase 1.
Follow Plasma Cell Myeloma: new trials by email Literature Review of Plasma Cell Myeloma trials Research Report on Plasma Cell Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant Belantamab Mafodotin, Lenalidomide - Plasma Cell Myeloma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 4 | 2024-08-19 | 2026-10-16 |
| Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Melphalan, Peripheral Blood Stem Cell Transplantation - Plasma Cell Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2024-01-27 | 2024-01-31 | |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma | Phase 3 | Recruiting | SWOG Cancer Research Network | 510 | 2023-10-12 | 2026-06-10 |
| CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma Infusion of CS1 CAR-T cell product - Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Myeloma | Phase 1 | Active not recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2023-07-05 | 2026-09-18 |
| Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma Zirconium Zr 89-DFO-YS5, Positron Emission Tomography / Computed Tomography (PET/CT), Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) - Multiple Myeloma, Plasma Cell Myeloma | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 20 | 2023-06-16 | 2026-09-16 |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone - Plasma Cell Myeloma | Phase 2 | Enrolling by invitation | Sanofi | 70 | 2023-04-05 | 2026-10-15 |
| Evaluation of Comprehensive Geriatric Assessment and Laboratory Biomarkers in Elderly Patients With Multiple Myeloma Biospecimen Collection, Comprehensive Geriatric Assessment, Electronic Health Record Review - Plasma Cell Myeloma | Completed | Mayo Clinic | 56 | 2023-02-15 | 2026-02-03 | |
| Home Based Daratumumab Administration for Patients With Multiple Myeloma Daratumumab and Hyaluronidase-fihj, Questionnaire Administration, Quality-of-Life Assessment - Plasma Cell Myeloma | Phase 4 | Completed | Thomas Jefferson University | 20 | 2022-11-08 | 2025-11-21 |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Vactosertib, Fludarabine Phosphate, Cyclophosphamide - Colorectal Cancer, Hematologic Malignancy | Phase 1 | Suspended | David Wald | 12 | 2022-09-09 | 2026-07-14 |
| Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study Bortezomib, Daratumumab, Dexamethasone - Plasma Cell Myeloma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 49 | 2022-08-11 | 2026-10-16 |
| Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma Belantamab Mafodotin, Dexamethasone, Pomalidomide - Plasma Cell Myeloma | Phase 2 | Recruiting | Emory University | 34 | 2022-07-21 | 2026-09-03 |
| Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol - Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma | Not applicable | Recruiting | Roswell Park Cancer Institute | 175 | 2022-06-28 | 2025-12-01 |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation Venetoclax, Fludarabine, Cyclophosphamide - Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1 | Phase 1 | Unknown | Melbourne Health | 18 | 2022-06-08 | 2023-08-01 |
| Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization Loratadine, Placebo, Questionnaire Administration - Plasma Cell Myeloma | Early Phase 1 | Recruiting | Rutgers, The State University of New Jersey | 70 | 2022-04-18 | 2026-05-29 |
| Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy Pembrolizumab - Plasma Cell Myeloma | Phase 2 | Withdrawn | Emory University | 2022-04-11 | 2024-07-03 | |
| Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant Quality-of-Life Assessment, Questionnaire Administration, Spiritual Therapy - Lymphoma, Plasma Cell Myeloma | Not applicable | Completed | Emory University | 30 | 2022-03-21 | 2024-04-16 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL BMF-219 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Biomea Fusion Inc. | 55 | 2022-01-24 | 2025-07-03 |
| Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors Best Practice, Exercise Intervention, Quality-of-Life Assessment - Plasma Cell Myeloma | Not applicable | Completed | City of Hope Medical Center | 33 | 2021-10-06 | 2025-05-30 |
| SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1 - COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm | Phase 2 | Active not recruiting | GeoVax, Inc. | 63 | 2021-09-27 | 2026-02-11 |
| Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Selinexor, Dexamethasone Oral, Daratumumab - Multiple Myeloma, Myeloma Multiple | Phase 2 | Active not recruiting | US Oncology Research | 73 | 2021-09-10 | 2025-01-16 |
Showing 20 of 96. Sign in to see all of them.
Multiple Myeloma (96) · Lymphoma, Non-Hodgkin (18) · Hodgkin Disease (14) · Leukemia, Lymphocytic, Chronic, B-Cell (14) · Leukemia, Myeloid, Acute (14) · Myelodysplastic Syndromes (14) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Hematologic Neoplasms (9) · Lymphoma (8) · Anemia, Aplastic (7) · Myeloproliferative Disorders (7) · Leukemia, Myeloid, Chronic-Phase (5) · Lymphoma, Mantle-Cell (5) · Primary Myelofibrosis (5)
Blood Protein Disorders (96) · Cardiovascular Diseases (96) · Hematologic Diseases (96) · Hemic and Lymphatic Diseases (96) · Hemorrhagic Disorders (96) · Hemostatic Disorders (96) · Immune System Diseases (96) · Immunoproliferative Disorders (96) · Lymphoproliferative Disorders (96) · Neoplasms by Histologic Type (96) · Paraproteinemias (96) · Vascular Diseases (96) · Neoplasms (93) · Neoplasms, Plasma Cell (93) · Lymphatic Diseases (29)
Dexamethasone (29) · Lenalidomide (27) · Calcium Dobesilate (15) · Cyclophosphamide (15) · daratumumab (14) · auricularum (12) · dexamethasone 21-phosphate (12) · dexamethasone acetate (12) · Melphalan (11) · Peripheral Blood Stem Cell Transplantation (11) · isatuximab (11) · Bortezomib (10) · Whole-Body Irradiation (10) · fludarabine phosphate (9) · Mycophenolic Acid (8)
Sanofi (12) · Mayo Clinic (11) · M.D. Anderson Cancer Center (10) · Emory University (7) · Fred Hutchinson Cancer Center (7) · Roswell Park Cancer Institute (7) · City of Hope Medical Center (5) · SWOG Cancer Research Network (4) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (3) · ECOG-ACRIN Cancer Research Group (2) · Memorial Sloan Kettering Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Rutgers, The State University of New Jersey (2) · Thomas Jefferson University (2) · Alliance for Clinical Trials in Oncology (1)
United States (92) · Italy (11) · France (10) · Spain (10) · Greece (9) · Czechia (8) · Australia (7) · Germany (6) · Japan (6) · China (5) · New Zealand (5) · Russia (5) · Taiwan (5) · Brazil (4) · Canada (4)
Jens Hillengass (4) · Ajay Nooka, MD, MPH (3) · Brenda Sandmaier (3) · Shaji Kumar (3) · Shaji Kumar, M.D. (2) · Adam Binder, MD (1) · Adam Garsa, MD (1) · Adam R Binder, MD (1) · Ajay K Nooka, MD,MPH,FACP (1) · Ajay K. Nooka, MD,MPH,FACP (1) · Alexander Lesokhin, MD (1) · Amrita Krishnan, MD (1) · Amrita Y Krishnan (1) · Andrzej Jakubowiak (1)
PMID 33980831, PMID 36108425, PMID 38573925, PMID 24144643, PMID 26468228, PMID 28483761, PMID 29246938, PMID 29467138, PMID 30862646, PMID 31833394, PMID 32499241, PMID 32586908, PMID 32603426, PMID 32710011, PMID 32816893, PMID 32866432, PMID 33095874, PMID 33308307, PMID 33619369, PMID 33839618, PMID 34048681, PMID 34050260, PMID 34097854, PMID 34182226, PMID 34272304, PMID 34800109, PMID 35285981, PMID 35641409, PMID 35737873, PMID 36239134, PMID 36329525, PMID 36372355, PMID 37156782, PMID 37316728, PMID 37479547, PMID 37584290, PMID 37970718, PMID 38299578, PMID 38832972, PMID 38993150, PMID 39067465, PMID 40109195, PMID 40461152, PMID 41758929, PMID 42041169, PMID 42166768, PMID 42363804, PMID 42456135, PMID 42537695
P30CA138292 (7), P30CA015704 (4), 2017 (3), P30CA033572 (3), U10CA032102 (3), 2019 (2), 2023 (2), P01CA078902 (2), P30CA015083 (2), P30CA072720 (2), U10CA180820 (2), UG1CA189823 (2), 2014 (1), 2016 (1), 4UL1TR000427-10 (1)